Alan L. Rubino Elected to Aastrom Biosciences' Board of Directors
30 September 2005 - 9:00PM
PR Newswire (US)
ANN ARBOR, Mich., Sept. 30 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) announced today that Alan L.
Rubino, a Principal with Watchung Partners, has been elected to the
Company's Board of Directors. He will serve as a Class III Director
whose term expires at Aastrom's Annual Meeting of Shareholders in
2006. Mr. Rubino has been appointed to the Board's Audit Committee.
"We are excited to welcome Alan Rubino to our Board, as he will be
an important industry resource for our Company," said R. Douglas
Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom.
"He is an experienced senior pharmaceutical and healthcare
executive with more than twenty-five years of industry knowledge,
and proven accomplishments in the commercialization of primary and
specialty pharmaceuticals, strategic and marketing leadership and
business development. Alan is well versed in various therapeutic
product areas and their respective markets, and he will be a key
strategic contributor as Aastrom develops groundbreaking products
in the area of human tissue regeneration and moves them toward the
marketplace." Mr. Rubino is currently a Principal with Watchung
Partners, a strategic consulting firm to the pharmaceutical,
biotech and healthcare industries. Prior to this, Mr. Rubino was
the Executive Vice President and General Manager for the Teams
Businesses at PDI, Inc., a diversified sales and marketing services
provider to the biopharmaceutical, medical devices and diagnostics
industries. Before joining PDI, Mr. Rubino was Senior Vice
President of the Pharmaceuticals Technology and Services Division
of Cardinal Health. He joined Cardinal Health as part of the
acquisition of BLPG, Inc., a healthcare marketing services company,
where he was the Executive Vice President and Managing Director.
Prior to joining BLPG, Mr. Rubino had a highly distinguished career
with Hoffmann-LaRoche (Roche) where he was a member of the U.S.
operating and executive committees since 1992. During his tenure at
Roche, he held a series of key executive positions in marketing,
sales, operations, and human resource management, culminating in
the position of Vice President, Business Operations. Mr. Rubino
received a B.A. in economics from Rutgers University with a minor
in biology and chemistry, and completed post-graduate work at
University of Lausanne and the Harvard Business School.
Additionally, Mr. Rubino serves on the Board of Rutgers Business
School for both Newark and New Brunswick. The addition of Mr.
Rubino to the Board immediately fills the position vacated by Ms.
Linda Fingerle, who has resigned from the Board of Directors to
pursue other professional activities. The Company thanks Ms.
Fingerle for her contributions and service. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is
developing patient-specific products for the repair or regeneration
of human tissues, utilizing the Company's proprietary adult stem
cell technology. Aastrom's strategic position in the tissue
regeneration sector is enabled by its proprietary Tissue Repair
Cells (TRCs), a mix of bone marrow-derived adult stem and
progenitor cells manufactured in the AastromReplicell(R) System, an
industry- unique automated cell production system. TRCs are the
core component of the products Aastrom is developing for severe
bone fractures, ischemic vascular disease, jaw reconstruction and
spine fusion, with Phase I/II level clinical trials active in the
U.S. and EU for some of these indications. For more information,
visit Aastrom's website at http://www.aastrom.com/. This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, and market
development plans, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "should," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly or Cameron Associates Becky Anderson Kevin McGrath -
Institutions Investor Relations Department Phone: (212) 245-4577
Aastrom Biosciences, Inc. Alyson Nikulicz - Media Phone: (734)
930-5777 Phone: (212) 554-5464 DATASOURCE: Aastrom Biosciences,
Inc. CONTACT: Kris M. Maly, or Becky Anderson, both of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath, Institutions,
+1-212-245-4577, or Alyson Nikulicz, Media Contact,
+1-212-554-5464, both of Cameron Associates Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024